Bicara Therapeutics Inc. Insider Trading
BCAX
Insiders sold $9.68M and bought nothing on the open market.
All of the selling was scheduled in advance under 10b5-1 plans. No executive or director has bought shares on the open market in the last two years.
Get an email when BCAX's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Sep 8 | Ryan Cohlhepp President, COO & Interim CEO | Sold10b5-1 plan 2 parts | 17,500 | $22.90 average | 401K | 8.8% | Form 4 |
| Aug 10 | Ivan Hyep Chief Financial Officer | Sold10b5-1 plan | 12,500 | $27.97 | 350K | 8.8% | Form 4 |
| Aug 10 | Claire Mazumdar Chief Executive Officer | Sold10b5-1 plan | 10,000 | $27.98 | 280K | 2.7% | Form 4 |
| Aug 10 | Ryan Cohlhepp President and COO | Sold10b5-1 plan | 18,750 | $27.98 | 525K | 9.4% | Form 4 |
| Jul 10 | Claire Mazumdar Chief Executive Officer | Sold10b5-1 plan 2 parts | 10,000 | $28.42 average | 284K | 2.7% | Form 4 |
| Jul 8 – 9 | Ryan Cohlhepp President and COO | Sold10b5-1 plan 4 parts | 28,750 | $28.98 average | 833K | 14% | Form 4 |
| Jul 8 | Ivan Hyep Chief Financial Officer | Sold10b5-1 plan 3 parts | 28,000 | $28.84 average | 808K | 18% | Form 4 |
| May 21 | Ivan Hyep Chief Financial Officer | Sold10b5-1 plan | 9,200 | $20.42 | 188K | 6.0% | Form 4 |
| May 18 | Claire Mazumdar Chief Executive Officer | Sold10b5-1 plan 2 parts | 15,000 | $20.04 average | 301K | 4.0% | Form 4 |
| May 15 | Ryan Cohlhepp President and COO | Sold10b5-1 plan 2 parts | 12,500 | $20.29 average | 254K | 6.1% | Form 4 |
| Apr 27 | David Raben Chief Medical Officer | Sold10b5-1 plan | 5,500 | $22.88 | 126K | 9.0% | Form 4 |
| Apr 21 | Ivan Hyep Chief Financial Officer | Sold10b5-1 plan | 9,200 | $23.00 | 212K | 6.0% | Form 4 |
| Apr 20 | Claire Mazumdar Chief Executive Officer | Sold10b5-1 plan | 15,000 | $23.61 | 354K | 4.0% | Form 4 |
| Apr 15 | Ryan Cohlhepp President and COO | Sold10b5-1 plan 2 parts | 12,500 | $23.01 average | 288K | 6.0% | Form 4 |
| Mar 25 | David Raben Chief Medical Officer | Sold10b5-1 plan | 5,500 | $18.95 | 104K | 9.0% | Form 4 |
| Mar 23 | Ivan Hyep Chief Financial Officer | Sold10b5-1 plan | 9,200 | $18.52 | 170K | 6.0% | Form 4 |
| Mar 18 – 20 | Claire Mazumdar Chief Executive Officer | Sold10b5-1 plan 3 parts | 15,000 | $18.82 average | 282K | 4.2% | Form 4 |
| Mar 16 | Ryan Cohlhepp President and COO | Sold10b5-1 plan 2 parts | 12,500 | $19.66 average | 246K | 5.9% | Form 4 |
| Mar 9 | Claire Mazumdar Chief Executive Officer | Sold10b5-1 plan | 36,766 | $19.17 | 705K | 9.8% | Form 4 |
| Mar 4 – 6 | Claire Mazumdar Chief Executive Officer | Sold10b5-1 plan 3 parts | 8,234 | $18.74 average | 154K | 2.4% | Form 4 |
| Mar 3 – 4 | Ivan Hyep Chief Financial Officer | Sold10b5-1 plan 2 parts | 16,518 | $18.23 average | 301K | 10% | Form 4 |
| Mar 3 – 4 | David Raben Chief Medical Officer | Sold10b5-1 plan 2 parts | 16,500 | $18.52 average | 306K | 23% | Form 4 |
| Mar 3 | Ryan Cohlhepp President and COO | Sold10b5-1 plan 2 parts | 17,392 | $18.16 average | 316K | 7.8% | Form 4 |
| Feb 26 | RA Capital Management, L.p. Large holder | Bought | 300,000 | $16.00 | $4.8M | 7.0% | Form 4 |
| Feb 25 | Ryan Cohlhepp President and COO | Sold10b5-1 plan 2 parts | 3,631 | $18.04 average | 66K | 1.7% | Form 4 |
| Jan 22 | Ryan Cohlhepp President and COO | Sold10b5-1 plan | 3,828 | $18.10 | 69K | 1.8% | Form 4 |
| Jan 22 | Ivan Hyep Chief Financial Officer | Sold10b5-1 plan | 1,882 | $18.15 | 34K | 1.3% | Form 4 |
| Jan 15 | Ryan Cohlhepp President and COO | Sold10b5-1 plan | 149 | $18.02 | 3K | <0.1% | Form 4 |
| Dec 22, 2025 | Ivan Hyep Chief Financial Officer | Sold10b5-1 plan | 9,200 | $18.31 | 168K | 6.0% | Form 4 |
| Dec 15, 2025 | Ryan Cohlhepp President and COO | Sold10b5-1 plan 2 parts | 12,500 | $18.68 average | 234K | 6.2% | Form 4 |
| Nov 24, 2025 – Nov 25, 2025 | David Raben Chief Medical Officer | Sold10b5-1 plan 3 parts | 11,000 | $18.65 average | 205K | 24% | Form 4 |
| Nov 24, 2025 | Claire Mazumdar Chief Executive Officer | Sold10b5-1 plan | 41,163 | $18.86 | 776K | 12% | Form 4 |
| Nov 21, 2025 – Nov 24, 2025 | Ivan Hyep Chief Financial Officer | Sold10b5-1 plan 2 parts | 18,400 | $18.54 average | 341K | 11% | Form 4 |
| Nov 21, 2025 | Ryan Cohlhepp President and COO | Sold10b5-1 plan 2 parts | 12,500 | $18.05 average | 226K | 6.1% | Form 4 |
| Oct 16, 2025 | Claire Mazumdar Chief Executive Officer | Sold10b5-1 plan | 24,103 | $18.83 | 454K | 7.2% | Form 4 |
| Oct 15, 2025 | Ryan Cohlhepp President and COO | Sold10b5-1 plan 2 parts | 12,500 | $18.16 average | 227K | 5.9% | Form 4 |
| Oct 13, 2025 – Oct 15, 2025 | Claire Mazumdar Chief Executive Officer | Sold10b5-1 plan 2 parts | 24,734 | $18.88 average | 467K | 7.4% | Form 4 |
| Oct 9, 2025 | David Raben Chief Medical Officer | Sold10b5-1 plan | 22,000 | $18.45 | 406K | 38% | Form 4 |
| Oct 9, 2025 | Ivan Hyep Chief Financial Officer | Sold10b5-1 plan | 6,415 | $18.23 | 117K | 4.2% | Form 4 |
| Oct 6, 2025 – Oct 8, 2025 | Ivan Hyep Chief Financial Officer | Sold10b5-1 plan 3 parts | 30,385 | $18.21 average | 553K | 17% | Form 4 |
- Sep 810b5-1 planRyan CohlheppPresident, COO & Interim CEO · sold 17,500 at avg $22.90401K8.8% of stake
- Aug 1010b5-1 planIvan HyepChief Financial Officer · sold 12,500 at $27.97350K8.8% of stake
- Aug 1010b5-1 planClaire MazumdarChief Executive Officer · sold 10,000 at $27.98280K2.7% of stake
- Aug 1010b5-1 planRyan CohlheppPresident and COO · sold 18,750 at $27.98525K9.4% of stake
- Jul 1010b5-1 planClaire MazumdarChief Executive Officer · sold 10,000 at avg $28.42284K2.7% of stake
- Jul 8 – 910b5-1 planRyan CohlheppPresident and COO · sold 28,750 at avg $28.98833K14% of stake
- Jul 810b5-1 planIvan HyepChief Financial Officer · sold 28,000 at avg $28.84808K18% of stake
- May 2110b5-1 planIvan HyepChief Financial Officer · sold 9,200 at $20.42188K6.0% of stake
- May 1810b5-1 planClaire MazumdarChief Executive Officer · sold 15,000 at avg $20.04301K4.0% of stake
- May 1510b5-1 planRyan CohlheppPresident and COO · sold 12,500 at avg $20.29254K6.1% of stake
- Apr 2710b5-1 planDavid RabenChief Medical Officer · sold 5,500 at $22.88126K9.0% of stake
- Apr 2110b5-1 planIvan HyepChief Financial Officer · sold 9,200 at $23.00212K6.0% of stake
- Apr 2010b5-1 planClaire MazumdarChief Executive Officer · sold 15,000 at $23.61354K4.0% of stake
- Apr 1510b5-1 planRyan CohlheppPresident and COO · sold 12,500 at avg $23.01288K6.0% of stake
- Mar 2510b5-1 planDavid RabenChief Medical Officer · sold 5,500 at $18.95104K9.0% of stake
- Mar 2310b5-1 planIvan HyepChief Financial Officer · sold 9,200 at $18.52170K6.0% of stake
- Mar 18 – 2010b5-1 planClaire MazumdarChief Executive Officer · sold 15,000 at avg $18.82282K4.2% of stake
- Mar 1610b5-1 planRyan CohlheppPresident and COO · sold 12,500 at avg $19.66246K5.9% of stake
- Mar 910b5-1 planClaire MazumdarChief Executive Officer · sold 36,766 at $19.17705K9.8% of stake
- Mar 4 – 610b5-1 planClaire MazumdarChief Executive Officer · sold 8,234 at avg $18.74154K2.4% of stake
- Mar 3 – 410b5-1 planIvan HyepChief Financial Officer · sold 16,518 at avg $18.23301K10% of stake
- Mar 3 – 410b5-1 planDavid RabenChief Medical Officer · sold 16,500 at avg $18.52306K23% of stake
- Mar 310b5-1 planRyan CohlheppPresident and COO · sold 17,392 at avg $18.16316K7.8% of stake
- Feb 26RA Capital Management, L.p.Large holder · bought 300,000 at $16.00$4.8M7.0% of stake
- Feb 2510b5-1 planRyan CohlheppPresident and COO · sold 3,631 at avg $18.0466K1.7% of stake
- Jan 2210b5-1 planRyan CohlheppPresident and COO · sold 3,828 at $18.1069K1.8% of stake
- Jan 2210b5-1 planIvan HyepChief Financial Officer · sold 1,882 at $18.1534K1.3% of stake
- Jan 1510b5-1 planRyan CohlheppPresident and COO · sold 149 at $18.023K<0.1% of stake
- Dec 22, 202510b5-1 planIvan HyepChief Financial Officer · sold 9,200 at $18.31168K6.0% of stake
- Dec 15, 202510b5-1 planRyan CohlheppPresident and COO · sold 12,500 at avg $18.68234K6.2% of stake
- Nov 24, 2025 – Nov 25, 202510b5-1 planDavid RabenChief Medical Officer · sold 11,000 at avg $18.65205K24% of stake
- Nov 24, 202510b5-1 planClaire MazumdarChief Executive Officer · sold 41,163 at $18.86776K12% of stake
- Nov 21, 2025 – Nov 24, 202510b5-1 planIvan HyepChief Financial Officer · sold 18,400 at avg $18.54341K11% of stake
- Nov 21, 202510b5-1 planRyan CohlheppPresident and COO · sold 12,500 at avg $18.05226K6.1% of stake
- Oct 16, 202510b5-1 planClaire MazumdarChief Executive Officer · sold 24,103 at $18.83454K7.2% of stake
- Oct 15, 202510b5-1 planRyan CohlheppPresident and COO · sold 12,500 at avg $18.16227K5.9% of stake
- Oct 13, 2025 – Oct 15, 202510b5-1 planClaire MazumdarChief Executive Officer · sold 24,734 at avg $18.88467K7.4% of stake
- Oct 9, 202510b5-1 planDavid RabenChief Medical Officer · sold 22,000 at $18.45406K38% of stake
- Oct 9, 202510b5-1 planIvan HyepChief Financial Officer · sold 6,415 at $18.23117K4.2% of stake
- Oct 6, 2025 – Oct 8, 202510b5-1 planIvan HyepChief Financial Officer · sold 30,385 at avg $18.21553K17% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with BCAX
Held by ETFs
BCAX is in 30 US ETFs. The largest of them, with BCAX's weight in each:
Spot a number that looks wrong? Check it in BCAX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BCAX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.